Considerations for Novel COVID-19 Mucosal Vaccine Development

Mucosal surfaces are the first contact sites of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Most SARS-CoV-2 vaccines induce specific IgG responses but provide limited mucosal immunity. Cytokine B-cell activation factor (BAFF) and A proliferation-inducing ligand (APRIL) in the t...

Descripción completa

Detalles Bibliográficos
Autor principal: Alturaiki, Wael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329946/
https://www.ncbi.nlm.nih.gov/pubmed/35893822
http://dx.doi.org/10.3390/vaccines10081173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329946/
https://www.ncbi.nlm.nih.gov/pubmed/35893822
http://dx.doi.org/10.3390/vaccines10081173

Ejemplares similares